... Committee of LungCancer Registry Prognosis of 6644 resected non- smallcelllung cancers in Japan: a Japanese lungcancer registry study LungCancer 2005, 50:227-34 11 Andre F, Grunenwald D, Pignon ... patients with non- smallcelllungcancer J Thorac Oncol 2010, 5:825-9 Ou SH, Zell JA: Validation study of the proposed IASLC staging revisions of the T4 and M non- smallcelllungcancer descriptors ... first line treatment for individuals with stage I-II NSCLC However, more than half of the patients with NSCLC are diagnosed with N2-3 or M1 disease [14] While chemotherapy for patients with advanced...
... Kim K, Fairclough D, Cella D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D: Comparison of survival and quality of life in advanced non- small- celllungcancer patients treatedwith two ... Tonato M: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non- small- celllung cancer: a randomized phase III study of the Italian LungCancer Project J Clin ... Int J Cancer 2001, 94:153-156 Non- smallCellLungCancer Collaborative Group: Chemotherapy in nonsmallcelllung cancer: a meta-analysis using updated data on individual patients from 52 randomized...
... escalation in non- small- celllungcancer Int J Radiat Oncol Biol Phys 2001, 49:23-33 Abratt RP, Bogart JA, Hunter A: Hypofractionated radiation for non- smallcelllungcancerLungCancer 2002, ... hypofractionated radiation therapy (3DHRT) for this group of patients is yet to be defined Hypofractionation may result in an increase of normal tissue effects and a careful evaluation of acute and ... treatment of stage I non- smallcelllungcancerLungCancer 2003, 41:1-11 Zimmermann FB, Bamberg M, Molls M, Jeremic B: Radiation therapy alone in early stage non- smallcelllungcancer Semin Surg...
... patients undergoing lungcancer surgery? Outcomes and quality of life before and after surgery Chest 2002, 122:21-30 El-Sherif A, Gooding WE, Santos R, Pettiford B, Ferson PF, Fernando HC, Urda SJ, ... appearance of radiation injury of the lungand clinical symptoms after stereotactic body radiation therapy (SBRT) forlung cancers: are patients with pulmonary emphysema also candidates for SBRT forlung ... Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin PF, Lo SS, Timmerman RD, McGarry RC: FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non- small- celllungcancerLungCancer 2007, 56:229-234...
... c d Figure The effects of dsRNA-EGFR on A549 (A) and SPC-A1 (B) cell count and colony formation (C) The effects of dsRNA-EGFR on A549 (A) and SPC-A1 (B) cell count and colony formation (C) Cells ... specific for EGFR also inhibited tumor cell growth To investigate the functional effect of the down regulation of the EGFR expression, we performed two experiments; one was a cell count assay and ... (d) FITC staining of cells transfected with dsRNA-EGFR (B) EGFR gene expression was quantified in both control and transfected cells by a flow cytometry with excitation and emission settings of...
... sensitivity of 36% and a specificity of 97% for L858R and a sensitivity of 40% and a specificity of 99% for E746-A750 In the present study, we found a sensitivity of 100% and a specificity of 100% for ... antibody and 79% for the exon 19 deletion antibody Brevet et al [14] reported a sensitivity of 84.6% and a specificity of 98.9% for E746-A750 and a sensitivity of 95.2% and a specificity of 98.8% for ... of specific antibodies against EGFR mutation proteins might be useful for the diagnosis and treatment of lungcancer Figure IHC analysis of EGFR mutations in five human NSCLC cell lines A549 and...
... Treatment of Cancer Quality-of-Life Questionnaire -Lung Cancer- 17 items; EQ-5D: EuroQoL-5 Dimensions; HRQL: Healthrelated Quality of Life; NSCLC: Non- SmallCellLung Cancer; SF-36: Short-Form 36 ... MW: Staging of smallcelland non- smallcelllungcancer University of Iowa Virtual Hospital; 1999 Hopwood P, Stephens RJ: Symptoms at presentation for treatment in patients withlung cancer: Implications ... of Quality of Life in the Supportive Care setting of the Big Lung Trial in Non- Small- CellLungcancer Journal of Clinical Oncology 2005, 30:7417-7427 Silvestri G, Pritchard R, Welch HG: Preferences...
... Editor-in-Chief of this journal Page of Tzelepatiotis E, Samaras N: Docetaxel versus docetaxel/cisplatin in patients withadvanced non- small- celllung cancer: preliminary analysis of a multicenter, randomized ... chemotherapy for non- operable patients with NSCLC The search for either molecular or genetic markers predictive for docetaxel sensitivity might constitute future targets of investigation Finally, ... response induced by first-line chemotherapy with single agent docetaxel in a patient withadvancednonsmallcelllungcancer World Journal of Surgical Oncology 2010 8:8 Conflict of interests The...
... Joyce P, Fisher P: Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced nonsmall celllungcancer ... Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non- smallcelllungcancertreatedwith concurrent chemotherapy and ... of pneumonitis risk from dose-volume histogram parameters of the lung in patients withlungcancertreatedwith 3-D conformal radiotherapy Strahlenther Onkol 2003, 179:548-556 Fay M, Tan A, Fisher...
... years (Figure 1) The 3-year OAS was 79% for the 85 stage IA patients treatedwith 48 Gy in fractions and 56% for the 37 stage IB patients (p = 0.05) The 3-year CSS was 91% for the former group and ... Stereotactic body radiotherapy for stage I lungcancerandsmalllung metastasis: evaluation of an immobilization system for suppression of respiratory tumor movement and preliminary results Radiat ... tumors with a maximum diameter of 1.5-3 cm, and 52 Gy in fractions for those with a maximum diameter larger than cm Assuming an a/b ratio of 10 Gy, the biological effective dose (BED) was 92 Gy for...
... records of patients with NSCLC who were treated at the University of Rochester from 2000-2008 with curative-intent radiotherapy (with or without chemotherapy) for stage III NSCLC or SBRT for limited ... Additional file and Figure The 2year and 5-year OS for all patients with stage III NSCLC was 43% and 7% respectively versus 43% and 14% for initial limited stage IV (p = 0.30) The OS calculated from ... stage and net GTV were assessed for affect on OS from date of initial NSCLC diagnosis as shown in Additional file On univariate analysis of OS from date of initial NSCLC diagnosis, GTV at time of...
... schedule of fractions of 20 Gy or fractions of 18 Gy and a conservative fractionation schedule of fractions of 12 Gy or fractions of 11 Gy could be allowed For type B models, the standard fractionation ... influence of different planning algorithms on the planning of stereotactic radiotherapy Therefore, an additional planning study was performed in 22 stage IA and stage 1B non- smallcelllungcancer ... Stereotactic hypofractionated high-dose irradiation for stage I nonsmall celllung carcinoma Cancer 2004, 101:1623-1631 El-Sherif A, Gooding WE, Santos R, Pettiford B, Ferson PF, Fernando HC, Urda...
... site of disease failure, followed by IFF and any ENF (p < 0.0001, log-rank test) Five of 115 patients developed ENF and only of ENFs were isolated ENFs Page of (page number not for citation purposes) ... Scientific Publication Office for their help with preparing this manuscript A preliminary analysis of this data was presented in abstract form at the 47th Annual Meeting of the American Society of ... rate for patients receiving definitive radiotherapy, withisolated ENF rates of 0% to 8% [5] Rosenzweig and colleagues recently published results for a series of 524 patients treated definitively...
... distortion of the vertebral body and the aorta without using meshes of these organs for deformable registration in e) a b c d e f Figuredeformed follow-up CTfollow-uptarget CT and deformed follow-up ... e f Figuredeformed follow-up CT using all targetat the end of treatment; c) difference image betweenorgans-at CT and follow-up nal cord; f) difference image between planning CT and deformed follow-up ... mm ± 1.2 mm for CTplan versus CTFU after DR was performed However, in two patients the performance of the DR was not sufficient for reliable analysis of the GTV shape in CTdeform and these two...
... in fractions of Gy for compensation of a split period For patients a dose of 55 Gy in daily fractions of 2.75 Gy was administered For one patient the mean lung dose was considered too high for ... and in Europe lungcancer is the most common cause of cancer related-death with an increasing incidence each year The majority of patients has Non- SmallCellLungCancer (NSCLC) and 75% has advanced ... radiotherapy with or without chemotherapy for the group treatedwith radiotherapy alone (18%), but the differences were not statistically significant Age and stage had no influence on DFS For local...
... 157,300 deaths from lungcancer [4] Lungcancer has traditionally been dichotomized into two groups based on the histological features of the tumor: smallcelland non- smallcelllungcancer NSCLC is ... patient’s name, and date of birth Statistics We have used the database to correlate proteomic information with clinical parameters for patients with nonsmall celllungcancer Within this database, ... with non- smallcelllungcancer comprise the majority of cases annotated within the database Other cancers contained in the database include smallcelllung cancer, mesothelioma, esophageal cancer, ...
... immunohistochemically for EGFR and COX-2 expression and their prognostic values were explored after deparaffinization and rehydration, the samples were treatedwith sodium citrate buffer and microwave for epitope ... detection of Figure Survival curves with different level of EGFR protein expression The solid blue line indicates the survival for EGFR negative and the green line represents survival for EGFR positive ... potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced nonsmall celllungcancer patients treatedwith erlotinib and celecoxib Clin Cancer...
... Multi-institutional randomized phase II trial of gefitinib for previously treated patients withadvanced non- small- celllungcancer (The IDEAL Trial) [corrected] J Clin Oncol 2003, 21:2237-2246 Page of 11 Kris ... MR: Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy foradvanced non- smallcelllung cancer: CALGB 9532 Lungcancer 2000, 28(1):63-68 17 Yang P, Allen MS, Aubry MC, Wampfler JA, Marks ... epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non- small- celllungcancertreatedwith chemotherapy alone and in combination with erlotinib...
... Level of Differentiation 0.474 0.518 Level of Differentiation 0.258 Poor Differentiated 40% Poor Differentiated 80% Moderate and Well Differentiated 21 19 47.50% Moderate and Well Differentiated ... Dianying, Shen Yali, Xu Feng, Wang Jin: EGFR and COX-2 protein expression in non- smallcelllungcancerand the correlation with clinical features Journal of Experimental & Clinical Cancer Research 2011, ... Li et al.: Correction: EGFR and COX-2 protein expression in non- smallcelllungcancerand the correlation with clinical features Journal of Experimental & Clinical Cancer Research 2011 30:32...
... failure The value of 1 8F- FDG PET/CT imaging for surveillance following lung SBRT deserves further study Abbreviations BED Gy3: biologic effective lung dose; BED Gy10: biologic effective tumor dose; ... radiotherapy for stage I non- smallcelllungcancer mature results for medically inoperable patients LungCancer 2006, 51:97-103 Lax I, Panettieri V, Wennberg B, et al: Dose distributions in SBRT of lung ... body radiotherapy (SBRT) for stage I non- small- celllungcancerLungCancer 2007, 56:229-234 17 Henderson MA, Hoopes DJ, Fletcher JW, et al: A pilot study of serial 18ffluorodeoxyglucose positron...